amelubant and Carotid-Stenosis

amelubant has been researched along with Carotid-Stenosis* in 1 studies

Other Studies

1 other study(ies) available for amelubant and Carotid-Stenosis

Article	Year
Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:4 The lipid-derived inflammatory mediators leukotrienes (LTs) are produced during vascular injury. The aim of the present study was to determine the role of LT receptor signaling in the pathophysiology of in-stent stenosis.. New Zealand White rabbits were fed 0.3% cholesterol and subjected to angioplasty with balloon dilatation and stent implantation in the right carotid artery. Rabbits treated for 2 weeks with the BLT receptor antagonist BIIL284 (3 mg/kg once daily by oral gavage) displayed a significantly reduced in-stent intimal hyperplasia in carotid arteries compared with vehicle-treated rabbits. In addition, BIIL284 treatment significantly reduced the extracellular matrix metalloproteinase (MMP)-2 and MMP-9 activities in stented arteries. The inhibited MMP-9 activity was correlated with decreased macrophage content in the lesions. The LTB(4)-induced migration of vascular smooth muscle cells was significantly inhibited by transfection with siRNA against MMP-2. Finally, human arteries subjected to ex vivo angioplasty and stent implantation displayed an increased in-stent intimal hyperplasia and higher MMP-2 and -9 activities in the presence of LTB(4).. These results suggest a key role of LT signaling in the extracellular matrix degradation associated with hyperlipidemia and in-stent stenosis. In conclusion, targeting LT receptors may represent a therapeutic strategy in atherosclerosis and interventional cardiology. Topics: Administration, Oral; Amidines; Angioplasty, Balloon; Animals; Carbamates; Carotid Artery, Common; Carotid Stenosis; Cell Line; Cell Movement; Cell Proliferation; Cholesterol, Dietary; Disease Models, Animal; Extracellular Matrix; Humans; Hyperplasia; Leukotriene Antagonists; Leukotriene B4; Macrophages; Male; Mammary Arteries; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Organ Culture Techniques; Rabbits; RNA Interference; RNA, Small Interfering; Secondary Prevention; Stents; Time Factors; Transfection	2009

Article

Year

Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis.

Arteriosclerosis, thrombosis, and vascular biology, 2009, Volume: 29, Issue:4

The lipid-derived inflammatory mediators leukotrienes (LTs) are produced during vascular injury. The aim of the present study was to determine the role of LT receptor signaling in the pathophysiology of in-stent stenosis.. New Zealand White rabbits were fed 0.3% cholesterol and subjected to angioplasty with balloon dilatation and stent implantation in the right carotid artery. Rabbits treated for 2 weeks with the BLT receptor antagonist BIIL284 (3 mg/kg once daily by oral gavage) displayed a significantly reduced in-stent intimal hyperplasia in carotid arteries compared with vehicle-treated rabbits. In addition, BIIL284 treatment significantly reduced the extracellular matrix metalloproteinase (MMP)-2 and MMP-9 activities in stented arteries. The inhibited MMP-9 activity was correlated with decreased macrophage content in the lesions. The LTB(4)-induced migration of vascular smooth muscle cells was significantly inhibited by transfection with siRNA against MMP-2. Finally, human arteries subjected to ex vivo angioplasty and stent implantation displayed an increased in-stent intimal hyperplasia and higher MMP-2 and -9 activities in the presence of LTB(4).. These results suggest a key role of LT signaling in the extracellular matrix degradation associated with hyperlipidemia and in-stent stenosis. In conclusion, targeting LT receptors may represent a therapeutic strategy in atherosclerosis and interventional cardiology.

Topics: Administration, Oral; Amidines; Angioplasty, Balloon; Animals; Carbamates; Carotid Artery, Common; Carotid Stenosis; Cell Line; Cell Movement; Cell Proliferation; Cholesterol, Dietary; Disease Models, Animal; Extracellular Matrix; Humans; Hyperplasia; Leukotriene Antagonists; Leukotriene B4; Macrophages; Male; Mammary Arteries; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Organ Culture Techniques; Rabbits; RNA Interference; RNA, Small Interfering; Secondary Prevention; Stents; Time Factors; Transfection

2009